

THE NOVEL H₂S-DONOR ISOTHIA25PROMOTES CARDIOPROTECTIVE EFFECT AGAINST MYOCARDIAL ISCHEMIA/REPERFUSION INJURY IN RAT HEARTS AND REDUCTION OF OXIDATIVE STRESS IN H9C2CELLS

Era Gorica¹, Lorenzo Flori¹, Valentina Citi¹, Eugenia Piragine¹, Beatrice Severino², Angela Corvino², Alma Martelli¹, Lara Testai¹, Giuseppe Caliendo², Vincenzo Calderone¹

¹Department of Pharmacy, University of Pisa, Pisa - Italy, ²Department of Pharmacy, School of Medicine, University of Naples "Federico II", Naples - Italy

Introduction: Hydrogen sulfide (H₂S) is an endogenous gasotransmitter, involved in the regulation of several biological functions. Even though it has been considered a well-known toxic gas, recent studies have described its important role in the regulation of cardiovascular homeostasis, and its deficiency is etiologically associated with several cardiovascular diseases. Therefore, the research of original moieties able to release H₂S represents a timely issue for drug discovery. In this work, the H₂S-releasing properties of the isothiocyanate ISOTHIA25 were evaluated and its protective effects in different models of myocardial injury were further investigated using H9c2 cell line (rat cardiomyoblasts) and a model of rat myocardial ischemia/reperfusion (I/R) injury.

Material and methods: The ISOTHIA25H₂S releasing properties have been detected both in a cell-free environment, using an amperometric approach, through an Apollo-4000 Free Radical Analyzer (WPI) detector, and in cell-based assays. In particular, the H₂S release after ISOTHIA25 incubation in H9c2 cells was detected by a spectrofluorometric method, using the Washington state probe -1 (WSP-1) dye. The protective effect of ISOTHIA25 was first evaluated *in vitro*: H9c2 were treated with the isothiocyanate for 1h, and then exposed to the oxidative stress using H₂O₂ 200 μM for 2h. Cell viability was then measured with the WST-1 method. Finally, the cardioprotective effect of this isothiocyanate was evaluated in an *ex vivo* rat model of myocardial I/R: male Wistar rats were treated *i.p.* with increasing concentrations of ISOTHIA25. After 2h, the animals were anaesthetized with sodium pentobarbital, sacrificed and the hearts were subjected to an I/R injury using the Langendorff apparatus. The ischemic area was detected by 1% aqueous solution of tetrazolium chloride.

Results: In the presence of organic thiols (L-Cysteine 4mM) ISOTHIA25 at the concentration of 1mM was able to release about 60 μM of H₂S. In the absence of organic thiols, the H₂S release was negligible. Furthermore, the incubation of Isothia-25 with the H9c2 cells led to a significant increase of the H₂S release into the cells in a concentration-dependent manner. ISOTHIA25 showed a significant and concentration-dependent protection effect against the oxidative stress, resulting in an almost total recovery of the H9c2 cell viability at the concentration of 1 μM. The cardioprotective effect was also confirmed in the *ex vivo* model: the treatment with ISOTHIA25 led to a decrease of the ischemic area of the left ventricle after the I/R injury. Accordingly, the lactate dehydrogenase LDH enzyme activity measured in the perfused Krebs solution resulted to be reduced.

Discussion and conclusions: ISOTHIA25 exhibits H₂S-releasing properties showed cardioprotective effects both *in vitro* and *ex vivo* models: it increased the cell viability in cells exposed to oxidative stress and reduced the ischemic area in isolated rat hearts against the I/R injury. Thus, this compound can be viewed as a promising pharmacological tool for the treatment of such disease.